Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD

Data ReadoutpositiveudenafilPositive

AI Analysis

Summary

Mezzion Pharma announced positive preclinical in vivo study results for udenafil, a PDE5 inhibitor, in an ADPKD model. The data demonstrates the potential of the compound in treating autosomal dominant polycystic kidney disease.

Clinical Trial Data

Phase

Preclinical

Primary Endpoint

Met

Outcome Details

Positive results from in vivo study of udenafil in ADPKD preclinical model

Importance:4/10

Sentiment:

0.70

PreclinicalIn VivoPDE5 InhibitorADPKDKidney Disease

Related Companies

$INTI

Read the original article

Published by PR Newswire Biotech on August 2, 2026 3:13 PM

Read Original